DEA should remove barriers to opioid use disorder treatment
March 2023
![](https://www.bigcitieshealth.org/wp-content/uploads/fly-images/7764/volodymyr-hryshchenko-m1Hq4ibP9rc-unsplash-640x360-c.jpg)
BCHC submitted comments to DEA about the proposed rule on the Expansion of Induction of Buprenorphine via Telemedicine Encounter.
BCHC urges DEA to:
eliminate the in-person evaluation when prescribing more than a 30-day supply of buprenorphine via telemedicine and to promulgate consistent policies across federal agencies;
promulgate a rule to allow prescribing of buprenorphine via telehealth permanently;
develop consistency across clinical settings and providers in reporting to prescription drug monitoring programs (PDMPs).
Read the full comment
Download now Read the full comment